Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 188.44 Million USD | 12.66% |
| 2023 | 167.57 Million USD | 1.5% |
| 2022 | 165.09 Million USD | 1.09% |
| 2021 | 163.32 Million USD | -11.37% |
| 2020 | 184.27 Million USD | 7.72% |
| 2019 | 171.06 Million USD | 16.82% |
| 2018 | 146.43 Million USD | 5.41% |
| 2017 | 138.92 Million USD | -10.87% |
| 2016 | 155.85 Million USD | -61.85% |
| 2015 | 408.56 Million USD | 24.72% |
| 2014 | 327.59 Million USD | 29.26% |
| 2013 | 253.44 Million USD | 4.9% |
| 2012 | 241.6 Million USD | -2.34% |
| 2011 | 247.4 Million USD | 15406.41% |
| 2010 | 1.59 Million USD | 34.64% |
| 2009 | 1.18 Million USD | -24.65% |
| 2008 | 1.57 Million USD | 125.04% |
| 2007 | 698.89 Thousand USD | -84.19% |
| 2006 | 4.41 Million USD | 100.61% |
| 2005 | 2.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 188.79 Million USD | 16.86% |
| 2024 Q2 | 161.55 Million USD | 0.0% |
| 2024 Q1 | 161.55 Million USD | -3.64% |
| 2024 Q4 | 188.79 Million USD | 0.0% |
| 2024 FY | 188.44 Million USD | 12.45% |
| 2023 Q2 | 168.05 Million USD | 3.94% |
| 2023 Q1 | 161.68 Million USD | -2.06% |
| 2023 FY | 167.57 Million USD | 1.5% |
| 2023 Q4 | 167.66 Million USD | -0.36% |
| 2023 Q3 | 168.27 Million USD | 0.13% |
| 2022 FY | 165.09 Million USD | 1.09% |
| 2022 Q3 | 164.56 Million USD | -2.59% |
| 2022 Q4 | 165.09 Million USD | 0.33% |
| 2022 Q1 | 162.07 Million USD | -0.76% |
| 2022 Q2 | 168.93 Million USD | 4.23% |
| 2021 Q2 | 168.57 Million USD | -3.15% |
| 2021 Q1 | 174.06 Million USD | -5.54% |
| 2021 FY | 163.32 Million USD | -11.37% |
| 2021 Q4 | 163.32 Million USD | -1.14% |
| 2021 Q3 | 165.19 Million USD | -2.01% |
| 2020 Q3 | 177.97 Million USD | -6.05% |
| 2020 Q4 | 184.27 Million USD | 3.54% |
| 2020 FY | 184.27 Million USD | 7.72% |
| 2020 Q1 | 178.63 Million USD | 4.43% |
| 2020 Q2 | 189.43 Million USD | 6.04% |
| 2019 Q1 | 161.19 Million USD | 10.08% |
| 2019 Q4 | 171.06 Million USD | -2.12% |
| 2019 Q2 | 163.77 Million USD | 1.6% |
| 2019 Q3 | 174.76 Million USD | 6.71% |
| 2019 FY | 171.06 Million USD | 16.82% |
| 2018 FY | 146.43 Million USD | 5.41% |
| 2018 Q4 | 146.43 Million USD | 20.3% |
| 2018 Q3 | 121.72 Million USD | 36.45% |
| 2018 Q2 | 89.2 Million USD | -20.57% |
| 2018 Q1 | 112.3 Million USD | -19.16% |
| 2017 Q3 | 138.75 Million USD | -7.72% |
| 2017 Q1 | 155.57 Million USD | -0.18% |
| 2017 Q4 | 138.92 Million USD | 0.12% |
| 2017 Q2 | 150.36 Million USD | -3.35% |
| 2017 FY | 138.92 Million USD | -10.87% |
| 2016 Q4 | 155.85 Million USD | -46.48% |
| 2016 FY | 155.85 Million USD | -61.85% |
| 2016 Q3 | 291.2 Million USD | -2.34% |
| 2016 Q2 | 298.19 Million USD | 638.12% |
| 2016 Q1 | 40.4 Million USD | -90.11% |
| 2015 Q4 | 408.56 Million USD | 0.0% |
| 2015 Q2 | 379.7 Million USD | 901.04% |
| 2015 Q1 | 37.93 Million USD | -88.42% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | 408.56 Million USD | 24.72% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | 327.59 Million USD | 727.95% |
| 2014 Q3 | 39.56 Million USD | -89.11% |
| 2014 Q2 | 363.33 Million USD | 0.0% |
| 2014 FY | 327.59 Million USD | 29.26% |
| 2013 Q4 | 253.44 Million USD | 381.34% |
| 2013 FY | 253.44 Million USD | 4.9% |
| 2013 Q2 | 226.89 Million USD | 0.0% |
| 2013 Q3 | 52.65 Million USD | -76.79% |
| 2012 FY | 241.6 Million USD | -2.34% |
| 2012 Q4 | 241.6 Million USD | 0.0% |
| 2011 FY | 247.4 Million USD | 15406.41% |
| 2010 FY | 1.59 Million USD | 34.64% |
| 2009 FY | 1.18 Million USD | -24.65% |
| 2008 FY | 1.57 Million USD | 125.04% |
| 2007 FY | 698.89 Thousand USD | -84.19% |
| 2006 FY | 4.41 Million USD | 100.61% |
| 2005 FY | 2.2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -686826.803% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1890.769% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -160.028% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -23199.459% |
| Rebus Holdings, Inc. | 5.24 Million USD | -3494.899% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -219.322% |
| Qrons Inc. | 1.48 Million USD | -12558.224% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -15268.018% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -151.528% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -421514.082% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1239.124% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -253.521% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1866.648% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -44600.886% |
| SQZ Biotechnologies Company | 50.03 Million USD | -276.596% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1469.225% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -4792.856% |
| Marizyme, Inc. | 26.67 Million USD | -606.428% |
| Genus plc | 485 Million USD | 61.145% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -3125.344% |
| Pharming Group N.V. | 244.07 Million USD | 22.792% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -9274.748% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -7388.874% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -4859.069% |
| ContraFect Corporation | 32.53 Million USD | -479.277% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -9411.122% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -4823.249% |
| IMV Inc. | 37.93 Million USD | -396.786% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1499.945% |
| MultiCell Technologies, Inc. | 1617.67 USD | -11649039.194% |
| ONE Bio Corp. | 27.49 Million USD | -585.358% |
| Accustem Sciences Inc. | 1.07 Million USD | -17360.88% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -143.415% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -8809.621% |
| Q BioMed Inc. | 8.13 Million USD | -2217.055% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -127.22% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -3561.938% |
| Biomind Labs Inc. | 1.49 Million USD | -12474.611% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -58.727% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1984.059% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -923.966% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -13042.462% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -132518.762% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -93599.472% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -3179.682% |
| GB Sciences, Inc. | 5.41 Million USD | -3378.406% |
| Alpha Cognition Inc. | 7.16 Million USD | -2530.155% |
| HST Global, Inc. | 593.59 Thousand USD | -31646.437% |
| CSL Limited | 18.62 Billion USD | 98.988% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -14865.508% |
| Halberd Corporation | 728.71 Thousand USD | -25759.711% |
| Enzolytics Inc. | 365.26 Million USD | 48.409% |
| Agentix Corp. | 2.51 Million USD | -7406.094% |
| Resverlogix Corp. | 67.39 Million USD | -179.608% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -22367.8% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 57.648% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -10894.436% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -661.515% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1483.156% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -5041.506% |
| AVAX Technologies, Inc. | 3.99 Million USD | -4618.494% |
| Zenith Capital Corp. | 27.56 Thousand USD | -683438.141% |
| Genscript Biotech Corporation | 1.32 Billion USD | 85.787% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -78861.438% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -4946.309% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -27578.499% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -6849.468% |
| Kadimastem Ltd | 3.5 Million USD | -5276.656% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -281459.01% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -274.91% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1084.839% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -40451.977% |
| LadRx Corporation | 2.2 Million USD | -8463.61% |
| Cell Source, Inc. | 15.8 Million USD | -1092.181% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3352.874% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3352.874% |
| NovAccess Global Inc. | 7.86 Million USD | -2297.291% |
| Affymax, Inc. | 8.87 Million USD | -2024.277% |
| Itoco Inc. | 1.65 Million USD | -11299.118% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -9085.409% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -3015.302% |
| Mobile Lads Corp. | 1.31 Million USD | -14246.788% |
| CytoDyn Inc. | 127.89 Million USD | -47.344% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -450735.259% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -11930.605% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1606.109% |
| SYBLEU INC | 681.41 Thousand USD | -27554.98% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2988.292% |
| International Stem Cell Corporation | 5.27 Million USD | -3471.056% |
| Bioxytran, Inc. | 3.24 Million USD | -5699.188% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -30012.164% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -3981.428% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -359.666% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -746.372% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -9204.13% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -3340.026% |
| Neutra Corp. | 973.52 Thousand USD | -19256.858% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -549.473% |
| PureTech Health plc | 125.58 Million USD | -50.056% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -4915.66% |
| IXICO plc | 1.9 Million USD | -9816.614% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -817.944% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -82.382% |
| CSL Limited | 18.62 Billion USD | 98.988% |
| Cellectis S.A. | 249.36 Million USD | 24.432% |